Investigators performed a pre-planned secondary analysis of the open-label, randomized Antihypertensive Treatment of Acute Cerebral Hemorrhage 2 study, specifically on the magnetic resonance images obtained during the intensive blood pressure lowering portion of the trial.
Outcomes in intracerebral hemorrhage are less severe in patients with prior NOAC use.
The results confirm that ischemic, hemorrhagic, and subarachnoid stroke have very different etiologies.
Researchers have observed an upward trend in the incidence of pregnancy-related spontaneous subarachnoid hemorrhage.
Results from a secondary analysis of the ENCHANTED trial add to a pile of weak data that likely will not affect clinical practice.
Surprisingly, no evidence was found to suggest that patients with these markers benefit from intensive blood pressure reduction.
Although spot sign predicted ICH expansion, it proved to be a less robust diagnostic marker than demonstrated by previous single-center cohort studies.
Patients with cirrhosis had a 2.17% per year incidence of stroke compared with 1.11% per year incidence of stroke in patients without cirrhosis.
Compared with other sources of ICH, those associated with arteriovenous malformations had lower odds of death.
Intensive antiplatelet therapy appears to reduce risk of recurrence immediately after stroke, but may pose risks further out.
